Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis

Kiflu G. Tesfamicael; Lijun Zhao; Rubén Fernández-Rodríguez; David L. Adelson; Michael Musker; Thomas M. Polasek; Martin David Lewis

doi:10.3389/fpsyt.2024.1276410

Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis

Kiflu G. Tesfamicael, Lijun Zhao, Rubén Fernández-Rodríguez, David L. Adelson, Michael Musker, Thomas M. Polasek, Martin David Lewis

Research output: Contribution to journal › Review article › peer-review

4 Citations (Scopus)

15 Downloads (Pure)

Abstract

Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis.

Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data.

Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU).

Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels.

Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.

Original language	English
Article number	1276410
Number of pages	13
Journal	Frontiers in Psychiatry
Volume	15
DOIs	https://doi.org/10.3389/fpsyt.2024.1276410
Publication status	Published - 11 Jul 2024
Externally published	Yes

Keywords

antidepressant
depression
genotyping panels
pharmacogenomics (PGx)
pharmacogenomics-guided prescribing

Access to Document

10.3389/fpsyt.2024.1276410Licence: CC BY

Final published versionFinal published version, 1.15 MBLicence: CC BY

Cite this

@article{522fc436deb44c9bb2bbbe71803b8d50,

title = "Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis",

abstract = "Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis. Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data. Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU). Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.",

keywords = "antidepressant, depression, genotyping panels, pharmacogenomics (PGx), pharmacogenomics-guided prescribing",

author = "Tesfamicael, {Kiflu G.} and Lijun Zhao and Rub{\'e}n Fern{\'a}ndez-Rodr{\'i}guez and Adelson, {David L.} and Michael Musker and Polasek, {Thomas M.} and Lewis, {Martin David}",

year = "2024",

month = jul,

day = "11",

doi = "10.3389/fpsyt.2024.1276410",

language = "English",

volume = "15",

journal = "Frontiers in Psychiatry",

issn = "1664-0640",

publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression

T2 - an umbrella review and updated meta-analysis

AU - Tesfamicael, Kiflu G.

AU - Zhao, Lijun

AU - Fernández-Rodríguez, Rubén

AU - Adelson, David L.

AU - Musker, Michael

AU - Polasek, Thomas M.

AU - Lewis, Martin David

PY - 2024/7/11

Y1 - 2024/7/11

N2 - Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis. Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data. Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU). Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.

AB - Aim: To determine the efficacy and safety of pharmacogenomics (PGx)-guided antidepressant prescribing in patients with depression through an umbrella review and updated meta-analysis. Methods: A comprehensive systematic search was conducted on PsycINFO, PubMed, Embase and the Cochrane databases. The pooled effect sizes of randomized controlled trials (RCTs) were expressed as mean differences for continuous data and risk ratios for noncontinuous data. Results: Patients who received PGx-guided medications were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to antidepressants than patients receiving treatment-as-usual (TAU). Conclusion: PGx-guided antidepressant prescribing improves the treatment of depression. However, the significance and magnitude of the benefit varies widely between studies and different PGx testing panels. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022321324.

KW - antidepressant

KW - depression

KW - genotyping panels

KW - pharmacogenomics (PGx)

KW - pharmacogenomics-guided prescribing

UR - http://www.scopus.com/inward/record.url?scp=85200216277&partnerID=8YFLogxK

U2 - 10.3389/fpsyt.2024.1276410

DO - 10.3389/fpsyt.2024.1276410

M3 - Review article

AN - SCOPUS:85200216277

SN - 1664-0640

VL - 15

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

M1 - 1276410

ER -

Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this